Next 10 |
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ASRT on July 3, 2024 06:04AM ET. ASRT was trading at $1.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...
2024-06-27 09:51:48 ET Summary Assertio Holdings, Inc. shares present a significant upside potential due to ongoing turnaround efforts and proven success in monetizing underappreciated pharma assets. The merger with Spectrum Pharmaceuticals saved Assertio from potential collapse a...
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief...
2024-05-30 16:55:01 ET In its annual 2024 Russell index reconstitution, about 213 companies will be added and 198 deleted from the Russell Microcap Index. Read the full article on Seeking Alpha For further details see: Nektar, Verastem among healthcare additions in Russe...
2024-05-30 15:54:21 ET The Russell 3000 index will have a new look on June 28, after the market closes, when 225 securities will be added and 144 securities will be deleted as part of the annual reconstitution. Following are some notable healthcare companies which will be added and ...
2024-05-29 07:23:57 ET More on Assertio Holdings Assertio Holdings Non-GAAP EPS of $0.11, revenue of $32.99M misses by $0.82M Seeking Alpha’s Quant Rating on Assertio Holdings Read the full article on Seeking Alpha For further details see: Assertio...
LAKE FOREST, Ill., May 29, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that its Board of...
2024-05-28 09:15:05 ET Alliance Global Partners analyst issues BUY recommendation for ASRT on May 28, 2024 07:04AM ET. ASRT was trading at $1 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
LAKE FOREST, Ill., May 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, ...
BUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORS PR Newswire Letter Expresses Several Significant Concerns and Recommends That Further Investigation is Warranted Urge...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
15.65%Change Percent:
Assertio Therapeutics Inc. Company Name:
ASRT Stock Symbol:
NASDAQ Market:
Assertio Therapeutics Inc. Website:
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ASRT on July 3, 2024 06:04AM ET. ASRT was trading at $1.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief...
LAKE FOREST, Ill., May 29, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that its Board of...